2009
Requests for reprints can be addressed to:
Bolhuis GK, Engelhart JJP, Eissens AC
Compaction Properties of Isomalt
Eur J Pharm Biopharm, 72, 621-625, 2009
Bolhuis GK, Rexwinkel EG, Zuurman K
Polyols as filler-binders for disintegrating tablets prepared by direct compaction
Drug Dev Ind Pharm, 35, 671-677, 2009
Heijerman H, Westerman E, Conway S, Touw D, Döring G, for the consensus working group 1
Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: A European consensus
J Cystic Fibrosis, 8, 295-315, 2009
Laksmana FL, Hartman Kok PJ, Frijlink HW, Vromans H, Van der Voort Maarschalk K
Development and Application of a Process Window for Achieving High-Quality Coating in a Fluidized Bed Coating Process
AAPS PharmSciTech, 10, 732-742, 2009
Laksmana FL, Hartman Kok PJ, Vromans H, Van der Voort Maarschalk K
Predicting the diffusion coefficient of water vapor through glassy HPMC films at different environmental conditions using the free volume additivity approach
Eur J Pharm Sci, 37, 545-554, 2009
Laksmana FL, Van Vliet LJ, Hartman Kok PJ, Vromans H, Frijlink HW, Van der Voort Maarschalk K
Quantitative image analysis for evaluating the coating thickness and pore distribution in coated small particles
Munnik P, de Boer AH, Wissink J, Hagedoorn P, Heskamp I, de Kruijf W, van Rijn CJ, Frijlink HW, Zanen P,
In Vivo Performance Testing of the Novel Medspray((R)) Wet Aerosol Inhaler
J Aerosol Med Pulm Drug Deliv, 22, 317-321, 2009
Rasyid HN, van der Mei HC, Frijlink HW, Soegijoko S, van Horn JR, Busscher HJ, Neut D
Concepts for increasing gentamicin release from handmade bone cement bead
Acta Orthop, 80, 508-513, 2009
Rottier BL, van Erp CJP, Sluyter TS, Heijerman HGM, Frijlink HW, de Boer AH
Changes in Performance of the Pari eFlow® Rapid and Pari LC Plus™ during 6 Months Use by CF Patients
J Aerosol Med Pulm Drug Deliv, 22, 263-269, 2009
Schellekens RCA, Olsder GG, Langenberg SMCH, Boer T, Woerdenbag HJ, Frijlink HW, Ko sterink JGW, Stellaard F
Proof-of-concept study on the suitability of 13C-urea as a marker substance for assessment of in vivo behaviour of oral colon-targeted dosage forms
Br J Pharmacol, 158, 532-540, 2009
Srinarong P, Faber JH, Visser MR, Hinrichs WLJ, Frijlink HW
Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants
Eur J Pharm Biopharm, 73, 154-161, 2009
Staniek A, Woerdenbag HJ, Kayser O
Taxomyces andreanae: a presumed paclitaxel producer demystified?
Planta Med, 75, 1561-1566, 2009
Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ
Economic evaluations of hepatitis B vaccination for developing countries
Expert Rev Vaccines, 8, 907-920, 2009
de Vries TW, Rottier BL. Gjaltema D, Hagedoorn P, Frijlink HW, de Boer AH
Comparative in vitro evaluation of four corticosteroi d metered dose inhalers Consistency of delivered dose and particle size distribution
Respir Med, 103, 1167-1173, 2009
de Waard H, Grasmeijer N, Hinrichs WLJ, Eissens AC, Pfaffenbach PP, and Frijlink HW
Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production.
Eur J Pharm Sci, 38, 224-229, 2009
Zijlstra GS, Wolting J, Prop J, Petersen AH, Hinrichs WLJ, Uges DRA, Kerstjens HAM, van der Bij W, Frijlink HW
The efficacy of a new pulmonary cyclosporine A powder formulation in the prevention of transplant rejection in rats
J Heart Lung Transplant, 28, 486-492, 2009
Zijlstra GS, Ponsioen B, Hummel S, Sanders NN, Hinrichs WLJ, de Boer AH, Frijlink HW
Formulation and process development of (recombinant human) deoxyribonuclease I as a powder for inhalation
Pharm Dev Techn, 14, 358-368, 2009
| Laatst gewijzigd: | 22 november 2012 16:41 |